Bold Therapeutics
Manufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
850 Hastings St W 515, Vancouver, Britis...Phone Number
(604) 262-9899Website
www.bold-therapeutics.comRevenue
<$5 MillionIndustry
About Bold Therapeutics
Bold Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel metallotherapeutics aimed at advanced cancer treatment. The company focuses on addressing unmet needs in oncology by leveraging the clinical benefits of metal-based therapeutics, with its lead candidate BOLD-100 showing promise in treating various gastrointestinal cancers. Bold Therapeutics is advancing its clinical trials, including a Phase 3 trial in metastatic colorectal cancer and a Phase 2/3 trial in bile duct cancer, while also pursuing designations for breakthrough therapy in gastrointestinal indications. With a veteran team and versatile technology, Bold Therapeutics aims to enhance the effectiveness of existing cancer therapies and improve patient outcomes.Explore more
Bold Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Bold Therapeutics
Compare insights from companies similar to Bold Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Bold Therapeutics Tech Stack
A closer look at the technologies used by Bold Therapeutics
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Bold Therapeutics
Sign Up For FreeTo access detailed company insights
Bold Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel metallotherapeutics aimed at advanced cancer treatment. The company focuses on addressing unmet needs in oncology by leveraging the clinical benefits of metal-based therapeutics, with its lead candidate BOLD-100 showing promise in treating vario... Read More
